Lasalocid

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Lasalocid
Accession Number
DB11423
Type
Small Molecule
Groups
Vet approved
Description

Lasalocid is an agent that presents antibacterial and coccidiostat activities. It is produced by strains of Streptomyces lasaliensis.

Structure
Thumb
Synonyms
Not Available
External IDs
RO 2-2985 / RO-2-2985
Categories
UNII
W7V2ZZ2FWB
CAS number
25999-31-9
Weight
Average: 590.798
Monoisotopic: 590.381868699
Chemical Formula
C34H54O8
InChI Key
BBMULGJBVDDDNI-OWKLGTHSSA-N
InChI
InChI=1S/C34H54O8/c1-9-25(31-21(6)18-34(11-3,42-31)26-16-17-33(40,10-2)23(8)41-26)30(37)22(7)28(35)19(4)12-14-24-15-13-20(5)29(36)27(24)32(38)39/h13,15,19,21-23,25-26,28,31,35-36,40H,9-12,14,16-18H2,1-8H3,(H,38,39)/t19-,21+,22+,23+,25+,26-,28+,31+,33-,34+/m1/s1
IUPAC Name
6-[(3R,4S,5S,7R)-7-[(2S,3S,5S)-5-ethyl-5-[(2R,5R,6S)-5-ethyl-5-hydroxy-6-methyloxan-2-yl]-3-methyloxolan-2-yl]-4-hydroxy-3,5-dimethyl-6-oxononyl]-2-hydroxy-3-methylbenzoic acid
SMILES
[H][C@@](C)(CCC1=C(C(O)=O)C(O)=C(C)C=C1)[C@]([H])(O)[C@]([H])(C)C(=O)[C@]([H])(CC)[C@@]1([H])O[C@@](CC)(C[C@]1([H])C)[C@@]1([H])CC[C@](O)(CC)[C@]([H])(C)O1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe risk or severity of bleeding can be increased when Lasalocid is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Lasalocid is combined with (S)-Warfarin.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Lasalocid is combined with 4-hydroxycoumarin.
AcenocoumarolThe risk or severity of bleeding can be increased when Lasalocid is combined with Acenocoumarol.
Adenovirus type 7 vaccine liveThe therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Lasalocid.
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Lasalocid.
Anthrax vaccineThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Lasalocid.
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Lasalocid.
Bacillus calmette-guerin substrain danish 1331 live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Lasalocid.
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Lasalocid.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Benson JE, Ensley SM, Carson TL, Halbur PG, Janke BH, Quinn WJ: Lasalocid toxicosis in neonatal calves. J Vet Diagn Invest. 1998 Apr;10(2):210-4. [PubMed:9576359]
  2. Blanchard PC, Galey FD, Ross F, Landgraf WW, Meyer H, Spiro N: Lasalocid toxicosis in dairy calves. J Vet Diagn Invest. 1993 Apr;5(2):300-2. [PubMed:8507714]
  3. Shlosberg A, Weisman Y, Klopfer U, Perl S: Neurotoxic action of lasalocid at high doses. Vet Rec. 1985 Oct 12;117(15):394. [PubMed:4060551]
  4. Espino L, Suarez ML, Mino N, Goicoa A, Fidalgo LE, Santamarina G: Suspected lasalocid poisoning in three dogs. Vet Hum Toxicol. 2003 Oct;45(5):241-2. [PubMed:14513890]
  5. Hagel RB: Liquid chromatographic determination of lasalocid in premixes. J Assoc Off Anal Chem. 1978 Sep;61(5):1070-3. [PubMed:721723]
  6. Fitzgerald PR, Mansfield ME: Efficacy of lasalocid against coccidia in cattle. J Parasitol. 1979 Oct;65(5):824-5. [PubMed:512778]
  7. Kronfeld DS: Lasalocid toxicosis is inadequately quantified for horses. Vet Hum Toxicol. 2002 Aug;44(4):245-7. [PubMed:12136977]
  8. Mitrovic M, Schildknecht EG, Marusich WL: Lasalocid in prevention of turkey coccidiosis. Poult Sci. 1979 Sep;58(5):1154-9. [PubMed:523380]
  9. Galitzer SJ, Oehme FW, Bartley EE, Dayton AD: Lasalocid toxicity in cattle: acute clinicopathological changes. J Anim Sci. 1986 May;62(5):1308-16. [PubMed:3722021]
  10. Segev G, Baneth G, Levitin B, Shlosberg A, Aroch I: Accidental poisoning of 17 dogs with lasalocid. Vet Rec. 2004 Aug 7;155(6):174-6. [PubMed:15357378]
External Links
KEGG Drug
D04671
ChemSpider
4514598
ChEBI
92181
ChEMBL
CHEMBL145347
HET
LSD
Wikipedia
Lasalocid
PDB Entries
4rzm

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00432 mg/mLALOGPS
logP4.91ALOGPS
logP7.67ChemAxon
logS-5.1ALOGPS
pKa (Strongest Acidic)2.64ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area133.52 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity162.8 m3·mol-1ChemAxon
Polarizability66.61 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as diterpene glycosides. These are diterpenoids in which an isoprene unit is glycosylated.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Terpene glycosides
Direct Parent
Diterpene glycosides
Alternative Parents
Diterpenoids / Salicylic acids / Benzoic acids / Fatty alcohols / Ortho cresols / Benzoyl derivatives / Toluenes / 1-hydroxy-4-unsubstituted benzenoids / Oxanes / Beta-hydroxy ketones
show 10 more
Substituents
Diterpene glycoside / Diterpenoid / Hydroxybenzoic acid / Salicylic acid or derivatives / Salicylic acid / Fatty alcohol / Benzoic acid or derivatives / Benzoic acid / Benzoyl / O-cresol
show 27 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Polyether polyketides (LMPK09000002)

Drug created on February 25, 2016 11:39 / Updated on September 02, 2019 19:24